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Abstract
Background: Attention deficit/hyperactivity disorder 
(ADHD), conduct disorder (CD), and sensation seeking (SS) 
have been consistently related to a higher risk of substance 
use (SU) and substance use disorder (SUD). Objectives: To 
investigate the relationship between ADHD and prevalence 
rates in males at age 20 and age 25, the initiation of SU and 
SUD after age 20, and the escalation of SU from age 20 to age 
25, and to explore the role of CD and SS in the relation of 
ADHD with SU and SUD initiation and escalation. Method: 
Data were obtained as part of the Cohort Study on Sub-
stance Use Risk Factors (C-SURF), which focused on young 
Swiss men aged 20 years at baseline and 25 years at follow-
up. Results: Participants who screened positive for ADHD at 
baseline exhibited a higher rate of SU and SUD than partici-
pants who screened negative. The presence of ADHD symp-
toms at age 20 predicted initiation of all SU between age 20 
and age 25, except for alcohol and smoking. After control-
ling for self-reported CD and SS, ADHD still predicted this 
late initiation of use of hallucinogens, meth-/amphetamines, 
and ecstasy/MDMA; non-medical use of ADHD medication 
and sedatives, and alcohol use disorder (AUD). No escalation 
of weekly drinking and smoking or annual cannabis use was 
observed from age 20 to age 25. Conclusion: Screened-pos-
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itive ADHD is an independent predictor of late SU and AUD, 
along with self-reported CD and SS. From a public health 
perspective, identifying ADHD is not only important in child-
hood and adolescence but also in early adulthood to guide 
specific interventions to lower risks of drug use initiation and 
the development of AUD in early adulthood.
© 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Various risk factors for substance use (SU) and sub-
stance use disorder (SUD) have been identified, including 
attention deficit/hyperactivity disorder (ADHD) and 
conduct disorder (CD) [1, 2]. Personality traits such as 
sensation seeking (SS) [3] also play an important role in 
initiation of SU and escalation into SUD. However, the 
association between these factors and SU has been ex-
plored primarily in cross-sectional studies; prospective 
studies on the course of SU are scarce.
ADHD, which involves inattention, hyperactivity, and 
impulsivity [4], is a common childhood disorder with an 
estimated worldwide prevalence of 3.4% in children and 
adolescents [5]. In approximately half to two-thirds of 
cases, childhood ADHD persists into adulthood [6, 7]. 
Both childhood and persistent ADHD are associated with 
a higher prevalence and a more severe and chronic course 
of SUD in adolescence and adulthood [7–11], indicating 
that ADHD contributes to earlier onset [12, 13] and lon-
ger duration [13, 14] of SUD. Biederman et al. [15] and 
Molina et al. [12] have reported a more rapid progression 
within 4 years from substance abuse to dependence 
among male adolescents with ADHD compared to those 
without ADHD. Further studies suggest that when indi-
viduals with ADHD develop SUD in adolescence, its 
prevalence remains stable until early adulthood [16–20]. 
Finally, it has been suggested that if individuals with 
ADHD do not develop SUD prior to early adulthood, 
their risk later in life is not elevated [19, 21]. However, 
only few studies have prospectively investigated the 
course of ADHD and SU in early adulthood, and there-
fore, it is not known whether ADHD is associated with 
(late) initiation or (adult) escalation of SU after age 20. 
Molina and Pelham [22] observed an association between 
ADHD persistence and higher rates of daily cigarette 
smoking, repetitive drunkenness, and alcohol-related 
problems in adolescents diagnosed with childhood 
ADHD. These adolescents were also 3 times more likely 
to have used inhalants, hallucinogens, cocaine, and non-
prescribed stimulant medication. Sibley et al. [23] showed 
that individuals diagnosed with ADHD in early child-
hood who began to use tobacco and cannabis in early ad-
olescence were 4–5 times more likely than people without 
ADHD to escalate to heavy use by the age of 18. These 
findings indicate that individuals with ADHD show com-
paratively earlier initiation and/or greater escalation in 
the use of certain substances between late adolescence 
and early adulthood than individuals without ADHD.
In general population and clinical samples, ADHD 
and CD were found to co-occur in 30–50% of cases, like-
ly as a result of shared genetic and common environmen-
tal influences [24, 25]. Some studies found that the asso-
ciation between ADHD and SUD is partly mediated by 
comorbid CD [23, 26, 27]. However, most studies show 
additive effects of ADHD and CD on SU outcomes, sug-
gesting that ADHD and CD likely contribute indepen-
dently to a higher risk of SUD; furthermore, in some cas-
es, ADHD could be a risk factor for development of CD 
[14, 17, 20, 22, 28–30]. Therefore, studies that explore as-
sociations between ADHD and the course of SU must 
control for CD.
Unlike ADHD and CD, SS is not a disorder but a per-
sonality trait. SS individuals willingly take physical, so-
cial, legal, and financial risks in pursuit of varied, novel, 
complex, and intense sensations and experiences [31]. 
Two recent longitudinal studies on predictors of SU ini-
tiation in adolescence and early adulthood have shown 
that SS contributes significantly to the onset of alcohol, 
cannabis, or other drug use [32, 33].
Literature that specifically explores the relationship 
between ADHD, CD, SS, and the course of SU is scarce. 
To our knowledge, only one cross-sectional study has 
explored these 3 factors as predictors of stimulant use 
(i.e., caffeine, cocaine, amphetamines, or non-prescribed 
ADHD medication) in a large sample of college students 
between 18 and 25 years of age [34]. ADHD, CD, and the 
Disinhibition subscale of the Brief Sensation Seeking 
Scale (BSSS) [35] were found to be related to non-pre-
scribed use of ADHD medication; only CD was associ-
ated with illegal drug use.
The present prospective study has the following aims: 
(1) to compare prevalence rates of SU and SUD in men 
screened positive for ADHD (ADHD S+) with those in 
men screened negative for ADHD (ADHD S−) at base-
line (age 20) and at 5-year follow-up (age 25); (2) to iden-
tify late initiation of SU and late development of SUD, 
that is, between age 20 and age 25; and (3) to examine the 
course/escalation of SU among all participants in a large 
sample of Swiss men in their early 20s, that is, from age 
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20 to age 25. This extends a previous study by Vogel et al. 
[30], which used the same dataset, by adding SS to ADHD 
and CD as a predictor and prolonging the observation 
period from 15 months to 5 years. Based on the results of 
Vogel et al., we expected that between age 20 and age 25, 
non-using ADHD S+ men will show increased late ini-
tiation of cannabis and other drug use (particularly stim-
ulants, including all types of amphetamines, non-pre-
scribed ADHD medication, and cocaine), but not late 
initiation of alcohol use or smoking compared to ADHD 
S− men. We also expected that ADHD S+ at age 20 would 
independently predict late SU initiation, particularly late 
initiation of stimulant use, even after controlling for the 
possible effects of CD and SS on this kind of late SU ini-
tiation. Finally, we expected that there would be no esca-
lation in alcohol, tobacco, or cannabis use between age 
20 and age 25 in the ADHD S+ nor in the ADHD S− 
group, because both the ADHD S+ and ADHD S− groups 
would most likely have already developed problematic 
use of these substances in late adolescence, that is, before 
age 20.
Materials and Methods
Participants and Procedures
This study analysed data from the longitudinal Cohort Study 
on Substance Use Risk Factors (C-SURF) [36], which examined SU 
patterns in young Swiss men. Participants were recruited from 3 
of Switzerland’s 6 army recruitment centres. In Switzerland, army 
recruitment is mandatory for men nearing 19 years of age, leading 
to a quasi-census of all young Swiss men. There were no preselec-
tion criteria (e.g., affluence or education), as in college student 
samples. In total, 15,066 Swiss men attended army recruitment in 
the 3 target centres between August 2010 and November 2011. 
Participants were assured of confidentiality and were assessed out-
side the military environment. Those who provided written in-
formed consent received the baseline questionnaire at their home 
address approximately 2 weeks later, which has to be completed 
either online or on paper. They were sent the follow-up question-
naire approximately 5 years after completing the baseline ques-
tionnaire.
Among all participants who were informed of the study during 
army recruitment, 7,556 (50.1% of the eligible population) con-
sented to participate. Of these, 5,987 (79.2%) filled out the baseline 
questionnaire, and 4,923 of these participated at the 5-year follow-
up (82.2%). Participants with missing data on ADHD (n = 12) and 
nicotine dependence (n = 309) were excluded from the analysis. 
The final sample included 4,602 participants (76.9%). Two pub-
lished reports showed that differences between respondents, non-
respondents, and non-consenters at baseline were small and there 
were some different SU trends [37, 38]. The study protocol (Pro-
tocol No. 15/07) was approved by the Lausanne University Medi-
cal School Clinical Research Ethics Committee.
Measures
Sociodemographic Characteristics, ADHD, CD, and SS
All assessment instruments can be found on the C-SURF web-
site [36]. ADHD, CD, SS, and sociodemographic characteristics, 
such as marital status, education, employment, and native lan-
guage, were assessed at baseline.
Current ADHD was assessed using the Adult ADHD Self-Re-
port Scale (ASRS-v1.1), a short screening tool developed by the 
World Health Organisation for use in the general population [39]. 
The ASRS includes 6 questions concerning the frequency of recent 
ADHD symptoms, based on the diagnostic criteria in the Diagnos-
tic and Statistical Manual of Mental Disorders, fourth Edition 
(DSM-IV) [40]. For each question, the respondents rate how often 
a symptom occurred over the preceding 12 months on a 5-point 
scale from 0 (never) to 4 (very often). Total scores range from 0 to 
24. As proposed by Kessler et al. [41], a score of 14 was defined as 
the cut-off point for ADHD S+ versus ADHD S−. In a sample of 
218 participants from the USA, Kessler et al. [41] found an esti-
mated sensitivity of 64.9% and an estimated specificity of 93.9% 
using this cut-off value.
CD in early adolescence was assessed retrospectively using the 
self-report version of the Mini International Neuropsychiatric In-
terview Plus, which measures 6 behaviours exhibited before age 15 
(e.g., destruction of property) [42] as part of the diagnostic criteria 
for antisocial personality disorder. In early adolescence, if two or 
more of the dichotomous items (no = 0; yes = 1) receive a response 
of “yes,” the participants were considered screened positive for CD.
SS was measured using the BSSS, an 8-item self-report scale 
derived from form V of the Sensation Seeking Scale (SSS-V) [35]. 
Its 4 subscales include “Thrill and Adventure,” “Experience Seek-
ing,” “Disinhibition,” and “Boredom Susceptibility.” Participants 
rate all items on a 5-point Likert scale from 1 (strongly disagree) to 
5 (strongly agree). Only the full scale mean was used in the analyses. 
Hoyle et al. [35] identified acceptable internal consistency (α = 
0.76), similar to that of this study (α = 0.81).
Substance Use
SU was measured at baseline and follow-up with a recall period 
of 12 months. Weekly alcohol use was assessed by asking partici-
pants whether they had consumed any type of alcohol in the pre-
ceding 12 months, the number of days per week they consumed 
alcohol, and the number of standard drinks (i.e., 10–12 g pure al-
cohol) they consumed on a typical day of drinking. “Drinking al-
cohol” was defined as having consumed at least one standard alco-
holic drink within the previous 12 months. “Binge drinking” was 
defined as consuming six or more standard drinks on one occasion 
at least monthly [43]. Alcohol use disorder (AUD) was assessed by 
a self-report questionnaire [44] based on the diagnostic criteria of 
the DSM-5 [4], which included 12 dichotomous items (yes/no) 
adapted from the Semi-Structured Assessment for the Genetics of 
Alcoholism that asked about problems related to alcohol use over 
the past 12 months [45, 46]. Participants who answered “yes” to 4 
or more of the questions were considered to have an AUD.
Weekly tobacco use was assessed by asking participants wheth-
er they had smoked in the preceding 12 months, the number of 
days per week they smoked, and the number of cigarettes they 
smoked on a typical smoking day. “Smoking” was defined as hav-
ing smoked more than 50 cigarettes, 15 cigars, or 10 pipes within 
the previous 12 months. Nicotine dependence was assessed using 
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the Fagerström Test (FTND) [47]; participants with a total score 
of 4 or higher were considered to have a nicotine dependence.
Annual cannabis use was assessed by asking participants 
whether they had used cannabis in the preceding 12 months, the 
frequency of cannabis use, and the number of hours spent under 
the influence of cannabis on typical days of use. “Cannabis use” 
was defined as having consumed cannabis at least once within the 
previous 12 months. Cannabis use disorder (CUD) was identified 
using the Cannabis Use Disorder Identification Test (CUDIT) 
[48]. Participants with a total score of 8 or higher were considered 
to have a CUD.
Use of any amount of any other illicit drug within the preced-
ing 12 months was measured by one question (yes or no). Illicit 
drugs included hallucinogens/psychedelics (e.g., mushrooms, psi-
locybin, peyote, LSD, phencyclidine [“PCP/angel dust”], 2C-B, 
and 2C-I), meth-/amphetamines (“speed”), MDMA/ecstasy, her-
oin, and cocaine/crack/freebase.
Non-medical use of prescription drugs was assessed by asking 
participants whether they had taken ADHD medication (e.g., 
methylphenidate [e.g., Ritalin®] or amphetamine sulphate [Ad-
derall®]) or sedatives (e.g., hypnotics or tranquilisers) without a 
prescription or for any reason other than those for which the sub-
stance is prescribed by a physician within the preceding 12 months.
Statistical Analyses
Statistical analyses were performed using IBM SPSS Version 
26. Sociodemographic characteristics, CD, SS, SU outcomes at 
baseline, and SU outcomes at 5-year follow-up were compared be-
tween the ADHD S+ and ADHD S− groups using Pearson’s χ2 tests 
with continuity correction where appropriate (for dichotomous 
variables) and independent t tests (for continuous variables). Par-
tial correlation analyses were conducted to assess associations be-
tween ADHD, CD, and SS (ra1, ra2, and ra3; see Fig. 1 for the analy-
sis structure), and bootstrap tests were conducted to obtain confi-
dence intervals (CIs) for the correlation coefficients (bias 
corrected and accelerated bootstrap CI; BCa CI).
Multiple logistic regressions were performed to obtain regres-
sion coefficients B and odds ratios (ORs) for late SU initiation (di-
chotomous outcomes) and development of an AUD, a nicotine 
dependence, or a CUD. Only baseline non-users of the given sub-
stance were included in these analyses. Consequently, the samples 
were different for each substance. Bivariate association was calcu-
lated to estimate ADHD’s predictive contribution to SU initiation 
(c), and adjusted association to estimate the direct effect of ADHD 
on SU (c′), statistically controlling for both CD and SS as covari-
ates. A significant value for c′ would indicate that ADHD at age 20 
is a significant independent predictor for SU initiation at age 25. 
The contributions of CD (b1) and SS (b2) to SU initiation were es-
timated after statistically controlling for the other 2 variables (i.e., 
ADHD and SS for b1, ADHD and CD for b2). Cohen’s d effect 
sizes were computed from the ORs according to the calculation 
formula of Borenstein et al. [49].
Escalation in standard drinks per week, cigarettes per week, 
and annual days of cannabis use was assessed using analysis of co-
ADHD symptoms
(Baseline)
Substance use
(Five-year follow-up)
Conduct disorder
(Baseline)
Sensa�on seeking
(Baseline)
c = ADHD  SU
b1 = CD  SU w/ADHD and SS
b2 = SS  SU w/ADHD & CD
c' = ADHD  SU w/CD & SS
ra1 = ADHD with CD w/SS
ra2 = ADHD with SS w/CD
ra3 = CD with SS w/ADHD
ADHD, conduct disorder, sensa�on seeking, and substance use
Fig. 1. Theoretical model of attention deficit/hyperactivity disor-
der (ADHD) as a predictor of substance use (SU), controlling for 
conduct disorder (CD) and sensation seeking (SS). Thick lines in-
dicate the direct paths c from ADHD at baseline to SU at 5-year 
follow-up and c′ from ADHD to SU controlled for CD and SS (not-
ed as ADHD → SU w/CD & SS; “w/” = “with”), path b1 from CD 
to SU controlled for ADHD and SS, and path b2 from SS to SU 
controlled for ADHD and CD. Dotted lines indicate partial cor-
relations of predictors: ra1 of ADHD with CD (w/SS), ra2 of ADHD 
with SS (w/CD), and ra3 of CD with SS (w/ADHD).
ADHD, Conduct Disorder, Sensation 
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variance, with differences in SU between 5-year follow-up and 
baseline as the dependent variables, ADHD as the factor, and CD, 
SS, and language as covariates. All participants (baseline users and 
non-users) were included in the analyses. Escalation of each sub-
stance was estimated based on the measures of standard drinks per 
week, cigarettes per week, and days of cannabis use per year. Lan-
guage was included as a covariate in all analyses because there was 
a significant language difference between the ADHD S+ and 
ADHD S− groups.
Results
Sociodemographic Characteristics and Prevalence of 
SU and SUD at Age 20 and Age 25
The ADHD S+ (4.2%) and ADHD S− (95.8%) groups 
had no statistically significant differences in sociodemo-
graphic characteristics, except that French-speaking par-
ticipants were significantly more often screened positive 
for ADHD than German-speaking participants. The 
ADHD S+ group was significantly more likely to have 
screened positive for CD and scored higher on SS than the 
ADHD S− group (see Table 1).
At baseline, an equivalent percentage of participants in 
both groups drank alcohol. However, the ADHD S+ 
group exhibited significantly higher rates of binge drink-
ing and AUD than the ADHD S− group. The ADHD S+ 
group was more likely than the ADHD S− group to use 
all other substances, to have a nicotine dependence, and 
to have a CUD.
ADHD symptoms were significantly related to CD 
(ra1 = 0.06, 95% BCa CI [0.024, 0.096], p < 0.001) and SS 
(ra2 = 0.23, 95% BCa CI [0.201, 0.260], p < 0.001), and CD 
was significantly related to SS (ra3 = 0.06, 95% BCa CI 
[0.034, 0.092], p < 0.001). Effect sizes were none to small 
(d = 0.12–0.48).
At 5-year follow-up, the significant differences be-
tween the 2 groups in SU, except alcohol use, remained 
similar to the baseline, with participants in the ADHD S+ 
group being more likely to binge drink and to use all types 
of substances. AUD, nicotine dependence, and CUD also 
showed results similar to baseline (see Table 2).
Initiation of SU from Age 20 to Age 25
Table  3 presents the bivariate and adjusted associa-
tions of ADHD with late SU initiation, AUD, nicotine 
dependence, and CUD, with corresponding B coefficients 
and ORs and their CIs. CD and SS also had direct effects 
(for an overview of the different paths, see Fig. 1). ADHD 
predicted all outcomes except initiation of alcohol use, 
binge drinking, smoking, and nicotine dependence, with 
Table 1. Comparison of sociodemographic characteristics, CD, SS, 
SU, and SUDs at baseline by screened ADHD status
ADHD S− 
n = 4,410 
(95.8%)
ADHD S+ 
n = 192 
(4.2%)
t or χ2
Sociodemographic characteristics
Age, years (mean ± SD) 19.96±1.21 20.10±1.27 1.28
Language, %
French 94.8 5.2 14.74***
German 97.2 2.8
Marital status, %
Single 95.1 97.4 1.54
Married/in a relationship 4.9 2.6
Education, %
Compulsory education 49.6 48.4 4.47
Vocational/high school 48.9 49.0
College 1.5 2.6
Employment status, %
Unemployed 7.1 8.0 2.29
Employed/self-employed 17.4 14.8
High school/college 
student
75.5 77.2
CD, % 18.2 31.2 19.20***
SS (mean ± SD) 3.02±0.86 3.39±0.78 5.79***
SU characteristics
Alcohol
Drinking alcohol 92.4 92.2 0.01
Binge drinking 45.1 54.5 6.06*
AUD 9.2 26.3 57.68***
Tobacco
Cigarette smoking 44.6 56.3 9.58**
Nicotine dependence 9.4 18.2 15.46***
Cannabis
Cannabis use 29.1 49.5 35.58***
CUD 7.4 19.8 36.92***
Illicit drugs
Hallucinogens 3.3 9.9 21.95***
Meth-/amphetamines 2.9 6.8 8.42**
Ecstasy/MDMA 3.1 8.4 13.97***
Cocaine/crack/freebase 2.6 8.9 24.12***
Non-medical use of prescription drugs
ADHD medication 1.5 6.3 22.01***
Sedatives 4.0 12.6 31.18***
Hallucinogens include psilocybin (“magic mushrooms”), LSD, 
and PCP; ADHD medication includes methylphenidate and am-
phetamine sulphate; sedatives include tranquilisers and hypnotics. 
Heroin was excluded due to small sample sizes. CD, conduct dis-
order; SS, sensation seeking; SU, substance use; SUD, substance 
use disorder; SD, standard deviation; AUD, alcohol use disorder 
CUD, cannabis use disorder; ADHD, attention deficit/hyperactiv-
ity disorder; ADHD S−, ADHD screened negative group (ASRS 
score <14); ADHD S+, ADHD screened positive group (ASRS 
score ≥14); ASRS, Adult ADHD Self-Report Scale. *  p < 0.05, 
** p < 0.01, *** p < 0.001.
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ORs ranging from 1.70 for cannabis use to 4.29 for ADHD 
medication use and effect sizes varying from small to 
large (d = 0.29–0.80). After controlling for CD and SS, 
ADHD’s associations with beginning to use hallucino-
gens, meth-/amphetamines, ecstasy/MDMA, ADHD 
medication, and sedatives decreased but remained signif-
icant; its association with AUD increased. ORs ranged 
from 1.81 for ecstasy/MDMA to 3.41 for ADHD medica-
tion, with corresponding effect sizes varying from small 
to medium (d = 0.33–0.68). Thus, except for initiation of 
cannabis and cocaine use and development of CUD, 
ADHD significantly predicted all illegal SUs independent 
of CD and SS.
Further analysis of the late initiation hypothesis re-
vealed the following results for CD and SS: After control-
ling for ADHD and SS, CD predicted development of 
AUD and CUD and beginning to use all other drugs ex-
cept non-prescribed ADHD medication. Significant ORs 
ranged from 1.49 to 2.46 and effect sizes from small to 
medium (d = 0.22–0.50). After controlling for ADHD 
and CD, SS also predicted development of AUD and 
CUD, binge drinking, and beginning to use all other sub-
stances except sedatives. Significant ORs ranged from 
1.36 to 2.57 and effect sizes varied from non-significant 
to medium (d = 0.17–0.52).
Escalation of Alcohol, Tobacco, and Cannabis Use 
from Age 20 to Age 25
Similar to baseline (Table 1), at 5-year follow-up, the 
ADHD S+ group showed significantly more binge drink-
ing and tobacco and cannabis use than the ADHD S− 
group (Table 2). However, there was no escalation in us-
age. Instead, after controlling for CD and SS, participants 
in the ADHD S+ group significantly reduced their tobac-
co use from baseline to 5-year follow-up, with a minor 
effect size (d = 0.17). The large standard deviations may 
prevent significant results, however (Table 4).
Discussion
This longitudinal study compared SU patterns in a 
large sample of young adult Swiss men, including 192 
who screened positive for ADHD (4.2%) and 4,410 who 
Table 2. Comparison of SU and SUDs at 5-year follow-up by screened ADHD status
ADHD S− % (n/N)a ADHD S+ % (n/N)a χ2
Alcohol
Drinking alcohol 93.2 (4,109/4,410) 94.3 (181/192) 0.20
Binge drinking 37.2 (1,641/4,406) 45.3 (87/192) 4.76*
AUD 8.2 (359/4,401) 20.8 (40/192) 35.69***
Tobacco
Cigarette smoking 39.7 (1,749/4,410) 54.2 (104/192) 15.50***
Nicotine dependence 9.5 (413/4,361) 16.1 (31/192) 8.57**
Cannabis
Cannabis use 28.8 (1,268/4,406) 46.4 (89/192) 26.48***
CUD 7.8 (345/4,407) 15.6 (30/192) 13.91***
Illicit drugs
Hallucinogens 4.3 (190/4,404) 10.4 (20/192) 14.34***
Meth-/amphetamines 3.7 (163/4,405) 10.4 (20/192) 19.99***
Ecstasy/MDMA 7.3 (321/4,405) 16.7 (32/192) 21.53***
Cocaine/crack/freebase 5.8 (256/4,406) 14.1 (27/192) 20.29***
Non-medical use of prescription drugs
ADHD medication 1.7 (74/4,402) 7.3 (14/192) 28.15***
Sedatives 5.2 (231/4,402) 14.1 (27/191) 25.63***
Hallucinogens include psilocybin (“magic mushrooms”), LSD, and PCP; ADHD medication includes 
methylphenidate and amphetamine sulphate; sedatives include tranquilisers and hypnotics. Heroin was excluded 
due to small sample sizes. ADHD, attention deficit/hyperactivity disorder; ADHD S−, ADHD screened negative 
group (ASRS score <14); ADHD S+, ADHD screened positive group (ASRS score ≥14); ASRS, Adult ADHD Self-
Report Scale; SU, substance use; SUD, substance use disorder; AUD, alcohol use disorder; CUD, cannabis use 
disorder. * p < 0.05, ** p < 0.01, *** p < 0.001. a n/N = number of participants who use the substance/total number 
of participants of the corresponding subgroup.
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Table 3. Initiation of alcohol drinking, binge drinking, cigarette smoking, cannabis use, and drug use and 
development of related use disorders from baseline to 5-year follow-up
B OR 95% CI Wald d
Drinking alcohol: ADHD S− (161/333), ADHD S+ (9/15)a
b1(CD → SU w/ADHD & SS) 0.36 1.43 0.77–2.65 1.27 0.20
b2(SS → SU w/ADHD & CD) −0.01 1.00 0.78–1.27 0.01 0.00
c(ADHD → SU) 0.47 1.60 0.56–4.60 0.76 0.26
c′(ADHD → SU w/CD & SS) 0.42 1.52 052–4.42 0.59 0.23
Binge drinking: ADHD S− (446/2,410), ADHD S+ (19/87)
b1(CD → SU w/ADHD & SS) 0.01 1.00 0.75–1.35 0.01 0.00
b2(SS → SU w/ADHD & CD) 0.21 1.23 1.08–1.39 10.46*** 0.11
c(ADHD → SU) 0.19 1.21 0.72–2.03 0.51 0.11
c′(ADHD → SU w/CD & SS) 0.14 1.14 0.68–1.93 0.25 0.07
AUD: ADHD S− (240/3,992), ADHD S+ (19/140)
b1(CD → SU w/ADHD & SS) 0.67 1.96 1.46–2.61 20.52*** 0.37
b2(SS → SU w/ADHD & CD) 0.46 1.59 1.34–1.87 29.66*** 0.26
c(ADHD → SU) 0.95 2.59 1.56–4.28 13.70*** 0.53
c′(ADHD → SU w/CD & SS) 0.82 2.78 1.36–3.80 9.87** 0.45
Cigarette smoking: ADHD S− (329/2,441), ADHD S+ (17/84)
b1(CD → SU w/ADHD & SS) 0.07 1.07 0.76–1.50 0.14 0.04
b2(SS → SU w/ADHD & CD) 0.31 1.36 1.18–1.57 18.00*** 0.17
c(ADHD → SU) 0.48 1.62 0.94–2.79 2.98 0.27
c′(ADHD → SU w/CD & SS) 0.33 1.27 0.79–2.44 1.27 0.13
Nicotine dependence: ADHD S− (203/3,951), ADHD S+ (9/157)
b1(CD → SU w/ADHD & SS) 0.31 1.36 0.96–1.92 2.99 0.17
b2(SS → SU w/ADHD & CD) 0.16 1.17 0.99–1.39 3.20 0.09
c(ADHD → SU) 0.13 1.14 0.57–2.27 0.14 0.07
c′(ADHD → SU w/CD & SS) 0.04 1.05 0.52–2.09 0.02 0.03
Cannabis use: ADHD S− (461/3,127), ADHD S+ (22/97)
b1(CD → SU w/ADHD & SS) 0.40 1.49 1.15–1.93 9.04** 0.22
b2(SS → SU w/ADHD & CD) 0.46 1.58 1.39–1.79 50.83*** 0.25
c(ADHD → SU) 0.53 1.70 1.05–2.77 4.59* 0.29
c′(ADHD → SU w/CD & SS) 0.41 1.50 0.92–2.47 2.60 0.22
CUD: ADHD S− (164/4,080), ADHD S+ (11/154)
b1(CD → SU w/ADHD & SS) 0.75 2.11 1.50–2.97 18.36*** 0.41
b2(SS → SU w/ADHD & CD) 0.45 1.56 1.28–1.91 19.20*** 0.25
c(ADHD → SU) 0.65 1.91 1.01–3.60 3.96* 0.36
c′(ADHD → SU w/CD & SS) 0.43 1.54 0.81–2.94 1.73 0.24
Hallucinogens: ADHD S− (139/4,256), ADHD S+ (15/172)
b1(CD → SU w/ADHD & SS) 0.50 1.65 1.12–2.38 7.12** 0.28
b2(SS → SU w/ADHD & CD) 0.86 2.35 1.87–2.96 53.55*** 0.47
c(ADHD → SU) 1.03 2.80 1.60–4.89 13.06*** 0.57
c′(ADHD → SU w/CD & SS) 0.69 2.00 1.12–3.56 5.55* 0.38
Meth-/amphetamines: ADHD S− (118/4,276), ADHD S+ (16/178)
b1(CD → SU w/ADHD & SS) 0.68 1.97 1.35–2.88 12.17*** 0.37
b2(SS → SU w/ADHD & CD) 0.78 2.17 1.70–2.78 37.98*** 0.43
c(ADHD → SU) 1.33 3.78 2.18–6.55 22.43*** 0.73
c′(ADHD → SU w/CD & SS) 1.04 2.83 1.60–4.99 12.83*** 0.57
Ecstasy/MDMA: ADHD S− (256/4,264), ADHD S+ (25/175)
b1(CD → SU w/ADHD & SS) 0.54 1.72 1.30–2.27 14.62*** 0.30
b2(SS → SU w/ADHD & CD) 0.94 2.57 2.16–3.06 111.13*** 0.52
c(ADHD → SU) 0.94 2.56 1.64–3.98 17.22*** 0.52
c′(ADHD → SU w/CD & SS) 0.59 1.81 1.14–2.87 2.65* 0.33
Cocaine/crack/freebase: ADHD S− (201/4,289), ADHD S+ (17/174)
b1(CD → SU w/ADHD & SS) 0.90 2.46 1.82–3.32 34.54*** 0.50
b2(SS → SU w/ADHD & CD) 0.71 2.02 1.67–2.45 52.95*** 0.39
c(ADHD → SU) 0.77 2.17 1.29–3.65 8.45** 0.43
c′(ADHD → SU w/CD & SS) 0.43 1.54 0.90–2.65 2.46 0.24
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screened negative (95.8%). Both at age 20 and at age 25, 
the ADHD S+ group had a higher prevalence of alcohol, 
cigarette, and cannabis use and related SUDs, illicit drug 
use, and non-medical use of prescription drugs. These 
findings are consistent with many studies on the rela-
tionship between SU, SUD, and ADHD in early adult-
hood, which have reported higher rates of use and misuse 
of a wide range of potentially addictive substances and a 
higher risk of SUD among individuals with ADHD [8, 
11].
ADHD at age 20 did not predict late initiation (be-
tween age 20 and age 25) of alcohol use, binge drinking, 
smoking, or cannabis use but was significantly associated 
with late initiation of 3 other drugs (hallucinogens, meth-/
amphetamines, and ecstasy/MDMA) and non-prescribed 
medications (ADHD medication and sedatives), with a 
medium effect size for meth-/amphetamines and a large 
effect size for non-prescribed ADHD medication. Molina 
et al. [12] found that adolescents with ADHD were more 
likely to begin using alcohol, tobacco, cannabis, and some 
B OR 95% CI Wald d
ADHD medication: ADHD S− (58/4,328), ADHD S+ (9/177)
b1(CD → SU w/ADHD & SS) 0.20 1.25 0.70–2.16 0.49 0.12
b2(SS → SU w/ADHD & CD) 0.64 1.90 1.36–2.65 14.14*** 0.35
c(ADHD → SU) 1.46 4.29 2.08–8.86 15.12*** 0.80
c′(ADHD → SU w/CD & SS) 1.23 3.41 1.63–7.16 10.55** 0.68
Sedatives: ADHD S− (196/4,220), ADHD S+ (17/165)
b1(CD → SU w/ADHD & SS) 0.41 1.51 1.08–2.12 5.65* 0.23
b2(SS → SU w/ADHD & CD) 0.03 1.03 0.87–1.22 0.12 0.02
c(ADHD → SU) 0.81 2.24 1.33–3.78 9.10** 0.45
c′(ADHD → SU w/CD & SS) 0.78 2.17 1.28–3.40 8.19** 0.43
Language was included as a covariate; the Wald statistic follows a χ2 distribution; d = Cohen’s d. Hallucinogens 
include psilocybin (“magic mushrooms”), LSD, and PCP; ADHD medication includes methylphenidate and 
amphetamine sulphate; and sedatives include tranquilisers and hypnotics. Heroin was excluded due to small 
sample sizes. See Figure 1 for the structure of the statistical analyses. ADHD, attention deficit/hyperactivity 
disorder; ADHD S−, ADHD screened negative group (ASRS score <14); ADHD S+, ADHD screened positive 
group (ASRS score ≥14); ASRS, Adult ADHD Self-Report Scale; CD, conduct disorder; CI, confidence interval; 
OR, odds ratio; SS, sensation seeking; SU, substance use; AUD, alcohol use disorder; CUD, cannabis use disorder. 
* p < 0.05. ** p < 0.01. *** p < 0.001. a Numbers in parentheses following the ADHD S− and ADHD S+ groups 
indicate the number of participants who initiated use or developed the disorder/total number of non-users or 
participants who did not have the disorder at baseline.
Table 3 (continued)
Table 4. Escalation of alcohol, tobacco, and cannabis use from baseline to 5-year follow-up
Substance use ADHD S− (mean ± SD) ADHD S+ (mean ± SD) F d
baseline 5-year 
follow-up
Δ5-year 
follow-up – 
baseline
baseline 5-year 
follow-up
Δ 5-year 
follow-up – 
baseline
Standard drinks per week 7.0±11.75 7.0±10.77 0.08±13.12 10.3±17.55 10.8±16.22 0.49±15.56 0.19 0.03
Cigarettes per week 20.0±41.96 18.3±40.90 −1.63±32.14 37.3±60.86 29.2±55.29 −8.10±38.16 4.89* 0.17
Days of cannabis use per year 24.3±75.12 24.5±77.42 0.24±70.04 50.2±106.33 48.2±108.74 −2.06±105.76 0.02 0.01
d = Cohen’s d. ns differ slightly due to missing data (i.e., ADHD S−, n = 4,346 to 4,368; ADHD S+, n = 188–189). Language, CD, and SS were included 
as covariates. ADHD, attention deficit/hyperactivity disorder; ADHD S−, ADHD screened negative group (ASRS score <14); ADHD S+, ADHD screened 
positive group (ASRS score ≥14); ASRS, Adult ADHD Self-Report Scale; SD, standard deviation; CD, conduct disorder; SS, sensation seeking. * p < 0.05.
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illicit drugs earlier than their peers, typically before the 
age of 15 or 16. Only a minority began using illegal drugs 
before the age of 17. Sibley et al. [23] also reported that 
adolescents began to use alcohol, tobacco, and cannabis 
around the age of 14–15 years. Because the mean age of 
the present study’s sample at baseline was 20 years, the 
sample may have been too old to observe subjects’ initial 
use of these substances.
ADHD remained a significant predictor of late initia-
tion of both illegal (except for cocaine) and non-medical 
prescription drugs with low to medium effect sizes, even 
after statistically controlling for both CD and SS. As re-
ported in numerous other studies, CD and SS also in-
creased the risk of beginning to use almost all substances 
independent of ADHD [15, 17, 20, 22, 28, 29, 32, 33]. In 
other words, both CD and SS exert additive effects on 
ADHD, rendering young men with both ADHD and CD 
and/or SS even more prone to SU initiation and SUD 
(i.e., AUD or CUD). Our findings suggest that ADHD 
carries a unique risk for SU initiation in early adulthood, 
independent of self-reported CD and SS [27]. Important-
ly, the risk of developing AUD after age 20 was almost 3 
times higher in the ADHD S+ group than in the ADHD 
S− group, suggesting rapid progression to alcohol depen-
dence even if having started drinking after age 20 [12, 
15].
Due to methodological reasons (i.e., cross-sectional 
assessment of predictors), no formal mediator analyses 
were performed in this study with the 3, only slightly, 
correlating predictors ADHD, CD, and SS. To date, 
only two prospective studies have revealed CD as a me-
diator between ADHD and SU. Brook et al. [26] exam-
ined only SUD, not SU initiation; Sibley et al. [23] in-
vestigated use of alcohol, tobacco, and cannabis but not 
other substances, such as stimulants or non-prescribed 
ADHD medication. Moreover, to our knowledge, no 
existing prospective study on the relationship of ADHD 
with SU initiation has controlled for SS. A cross-sec-
tional study by van Eck et al. [34] reported that SS (i.e., 
higher scores on the Disinhibition subscale of the BSSS) 
moderated between ADHD and increased misuse of 
ADHD medication. However, no moderating effect was 
found for other stimulants, and no other substances 
were examined.
An important finding of the present study was that af-
ter adjusting for CD and SS, alcohol and cannabis use re-
mained stable in both groups from baseline to 5-year fol-
low-up. This indicates that the ADHD S+ group contin-
ued to use these substances more heavily than the ADHD 
S− group. The ADHD S+ group only very slightly de-
creased their cigarette smoking compared to the ADHD 
S− group, perhaps because they switched to using other 
substances examined in the study. Alternatively, they 
might have reached their peak use of alcohol, tobacco, 
and cannabis before baseline, and, at least with respect to 
smoking, begun to grow out of these consumption pat-
terns by the 5-year follow-up. Molina et al. [12] observed 
an escalation of alcohol, tobacco, cannabis, and illicit 
drug use throughout adolescence until the age of 21, and 
a decline in alcohol, tobacco, and cannabis use thereafter. 
Another study by Estévez-Lamorte et al. [50], using the 
same sample as Vogel et al. [30], found that a subsample 
of the ADHD S+ group showed maturation out of alco-
hol, nicotine, and CUDs and risky cannabis use. Breyer et 
al. [16] and Levy et al. [19] did not observe any change in 
SUD prevalence rates over time. However, they examined 
only substance dependence as an outcome and did not 
consider use patterns.
This study has important clinical implications. Use of 
the ASRS, an easily applicable screening instrument for 
ADHD, could help to identify young adult men at high 
risk for the initiation of various drugs, including stimu-
lants and sedatives, and for persistent heavy use of alco-
hol, tobacco, and cannabis. SS contributes independently 
to an elevated risk of initiating use of any substance except 
alcohol and sedatives, and CD to an elevated risk of any 
substance except alcohol, tobacco, and non-prescribed 
ADHD medication. These findings may be of specific in-
terest within the context of secondary prevention pro-
grammes or primary care, allowing a focus on men at high 
risk in early adulthood.
This study’s results should be interpreted in the con-
text of some strengths and limitations. The sample’s age 
homogeneity from 20 to 25 is a considerable strength, as 
this age group is at particularly high risk for SU and the 
prevalence of SU varies greatly across diverse age groups 
[51]. Considering that only a minority (about 4%) of in-
dividuals both have ADHD and use illegal drugs, the 
study’s large sample size allowed for collection of more 
information to make reliable observations. Another 
strength is the study’s longitudinal design, which ob-
served the course of SU from baseline to later follow-up 
measures [36].
The study also has limitations. First, the sample in-
cluded only men, who are more likely to have ADHD, 
CD, and SS, and generally exhibit higher rates of SU than 
women. Thus, the results may not be generalised to the 
female population. However, in a meta-analysis, Lee et 
al. [8] did not observe sex differences in the increased risk 
of individuals with ADHD developing SUD. Second, re-
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cruiting in military centres implies that only men with a 
Swiss passport were included in the sample. Non-Swiss 
permanent residents, who represent about one-fourth of 
the Swiss population, or individuals with dual citizen-
ship, who fulfilled their military obligations in the other 
country, were thus not considered. Third, ADHD was 
assessed using the ASRS screening instrument rather 
than the structured diagnostic interviews; thus, the diag-
nosis of ADHD was not confirmed via extensive clinical 
examination. ADHD may be underreported since the 
most frequently used cut-off in comparable studies with 
a score of 14 points may set too high, leading to a very 
conservative estimate of the ADHD prevalence due to 
false-negative cases. Luderer et al. [52] suggested that 
lowering the cut-off among individuals with AUD de-
creases the rate of false-negative cases. However, their 
results are based on a sample of patients attending resi-
dential treatment for alcohol dependence, a sample that 
is considerably different from our general population 
sample of young adult Swiss men. Likewise, CD, SS, and 
SU were based on self-report questionnaires, meaning 
some men may have under- or over-reported their 
ADHD, CD, SS, SU, or SUD for a variety of reasons (e.g., 
difficulty in recalling quantity and frequency of SU). 
However, the assessment instruments have been validat-
ed [35, 41, 43, 47, 48, 53], and previous studies have dem-
onstrated, in particular, the reliability and validity of us-
ing self-report screening instruments, for example, to as-
sess ADHD, in the context of SUD in adults [54]. Fourth, 
prevalence rates of CD were quite high, most likely of 
non-clinical assessment and wording of questions, per-
mitting rather common behaviours in adolescents to be 
rated as CD symptoms, which may have resulted in false-
positive cases. However, CD was used as a control vari-
able and non-differential misclassification of false-posi-
tive should bias the OR of ADHD towards the null and 
may have resulted in conservative estimates.
Conclusions
ADHD is a risk factor for late initiation of stimulant 
use (meth-/amphetamines and non-medical use of 
ADHD medication), hallucinogens, and non-prescribed 
sedatives as well as for the development of new AUD after 
age 20 and is associated with heavy (but not escalating) 
alcohol, tobacco, and cannabis use. CD and SS contribute 
independently to the risk of new AUD or CUD and late 
initiation of any substance except for alcohol, in case of 
CD except for smoking and non-medical use of ADHD 
medication, and in case of SS except for sedatives. From 
a public health perspective, identifying ADHD in child-
hood or adolescence and continuous treatment and sup-
port would be best to lower risks of SU and SUD, but 
identification of ADHD in early adulthood may be still 
relevant for that start of specific ADHD and SU interven-
tions.
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